Navigation Links
The Quigley Corporation Reports Fourth Quarter and 2008 Annual Results; Continues To Invest In Pharmaceutical R&D Future
Date:2/26/2009

ollecting all the patient information from 21 Study centers and conferring with its panel of experts on the data, will draft and report study conclusions, as they are available.

The Phase IIb study was designed to evaluate the safety and efficacy of QR-333, a unique topical formulation designed to offer physicians and patients an effective, easy to administer, safe treatment for diabetic peripheral neuropathy with little to no side effects. To date there is no fully effective treatment for diabetic neuropathy. Current treatment options are limited to products such as NSAIDs, analgesics, anticonvulsants, antidepressants, etc., which are often not well tolerated by patients.

Quigley Pharma generated positive results of its study to determine the duration of the anti-viral effect of QR448(a), a veterinary anti-viral compound against Infectious Bronchitis Virus (IBV) in commercial broiler chickens, a consumer meat type bird. QR448(a) also prevented the transmission of IBV from infected to non-infected 2 week old commercial broiler chickens, a consumer meat type bird.

Veterinary poultry products industry experts and those familiar with prevention and control of IBV recognize that abating transmission is perhaps one of the most important ways to economically prevent, control and manage potential losses due to IBV outbreaks.

During the first quarter of 2009, the Company signed a license with assignment of ownership agreement with Levlad, LLC/Natures Gate, a manufacturer and marketer of personal care products based on botanicals, for its patented formulation QR-340, a clinically tested compound developed by Quigley Pharma, shown to improve the appearance of scars. The general terms of the agreement allow the assignee to further refine, develop and commercialize the product with exclusivity and eventual full ownership of the patent within five years, beginning January 2009, with required roya
'/>"/>

SOURCE Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Quigley Announces Completion of Phase IIb Clinical Study of QR-333 For Diabetic Peripheral Neuropathy on November 25, 2008; Collection and Evaluation of Study Data to Begin Immediately Thereafter
2. The Quigley Corporation Reports Third Quarter 2008 Results; Continues Investment in Pharmaceutical R&D Future
3. The Quigley Corporation Names Gerard M. Gleeson to Succeed Retiring George J. Longo as Chief Financial Officer and Director
4. The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future
5. The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007
6. The Quigley Corporation Announces Sale of Its Health and Wellness Segment
7. Service Corporation International Announces Fourth Quarter 2008 Financial Results and Comments on Outlook for 2009
8. Heyltex Corporation to Become Exclusive Distributor of ThyroShield(R)
9. CUREXO Technology Corporation Announces 510(k) Submission to FDA for Total Knee Arthroplasty Application
10. Providence Service Corporation Announces Bylaw Amendments to Improve Corporate Governance
11. Service Corporation International Announces Schedule for Its Fourth Quarter 2008 Earnings Release and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... May 05, 2015 Buckeye Health Plan ... new CEO and plan president of Buckeye Health Plan. ... the position immediately. , Hill has more than 28 ... the Pacific Northwest, from managed care to large health ... and CEO of HealthPlus of Michigan, a health plan ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 Igantia ... San Francisco, leads an international initiative to examine key ... extend the human lifespan. Scientists at Igantia believe ... women, from the initiation of her menstrual cycle to ... mechanism for aging and, ultimately, extend the lifespan. ...
(Date:5/5/2015)... 2015 HealthSlide, Inc ., ... solutions for hospitals nationwide, has announced the launch ... CIOs and CTOs can access the calculator on ... both initial and ongoing savings of switching to ... nation’s hospitals pay an average of $300,000 a ...
(Date:5/5/2015)... 05, 2015 After record-breaking sales of ... 2014, Walgreens introduces the Cookies & Cream flavor at ... Extend Nutrition has continually raised the bar for nutritional ... combined with an unprecedented nutritional profile, backed by international ... Extend Nutrition will launch additional new products and expand ...
(Date:5/5/2015)... May 05, 2015 Every year, news articles ... Turns out, the worst dry eye season is spring, also ... in most of the United States. The only season offering ... advocate Sharon Kleyne, host of the Sharon Kleyne Hour™ Power ... her radio show of May 11, 2015. Kleyne is the ...
Breaking Medicine News(10 mins):Health News:Buckeye Health Plan Announces New Chief Executive Officer 2Health News:Buckeye Health Plan Announces New Chief Executive Officer 3Health News:Igantia Announces Digital Initiative to Decode Longevity 2Health News:HealthSlide Launches ROI Cost Calculator 2Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 2Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 3Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 4Health News:Nature’s Tears EyeMist tear film supplement soothes dry eye caused by spring pollen season, reports inventor Sharon Kleyne 2Health News:Nature’s Tears EyeMist tear film supplement soothes dry eye caused by spring pollen season, reports inventor Sharon Kleyne 3
... Financing Provides Capital to Complete EVEREST Pivotal Study and Begin ... European Commercialization ... Investors, MENLO PARK, Calif., Dec. 4 Evalve, Inc., the leader ... that it had successfully completed a $60 million Series D,financing. BBT Fund ...
... Bivalirudin lowers bleeding risk for patients undergoing bypass, study ... newer kind of anticlotting drug is safe over the ... heart attacks. , The drug, a "direct thrombin inhibitor" ... during cardiac procedures such as bypass surgery. , "We ...
... some truth to the popular wisdom that plump babies are ... people who had a low birth weight are more likely ... found that even people who had just mild or moderate ... smaller babies than those who had better mental health, said ...
... of New Orleans residents in months after the disaster, study ... the people living in New Orleans and about one-quarter of ... signs of a mood or anxiety disorder five to seven ... Researchers surveyed 1,043 residents in Louisiana, Alabama and Mississippi. , ...
... TARRYTOWN, N.Y., Dec. 4 EpiCept Corporation,(Nasdaq and OMX ... offering of 3,333,333 million shares of its common stock ... to approximately 1,666,667,million shares of common stock at an ... $4.7 million in net proceeds from the,offering. Rodman & ...
... Nabi,Biopharmaceuticals (Nasdaq: NABI ) announced ... assets constituting its Biologics strategic business unit ... of Biotest,AG, for $185 million in cash. ... has acquired or will acquire the Biologics ...
Cached Medicine News:Health News:UPDATED: Evalve(R) Completes $60 Million Series D Financing 2Health News:UPDATED: Evalve(R) Completes $60 Million Series D Financing 3Health News:Newer Anticlotting Drug Safe, Effective for Heart Surgeries 2Health News:Newer Anticlotting Drug Safe, Effective for Heart Surgeries 3Health News:Smaller babies more prone to depression, anxiety later on 2Health News:Many Katrina Survivors Suffered Psychological Symptoms 2Health News:EpiCept Corporation Announces Pricing of Public Offering 2Health News:EpiCept Corporation Announces Pricing of Public Offering 3Health News:Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG 2Health News:Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG 3
(Date:5/5/2015)... Omeros Corporation (NASDAQ: OMER ), ... commercializing both small-molecule and protein therapeutics for large-market ... and disorders of the central nervous system, today ... quarter 2015 financial results for the period ended ... after market close. Omeros management will host a ...
(Date:5/5/2015)... 2015  InMed Pharmaceuticals Inc. ("InMed") (CSE: IN; ... specializes in developing safer, more effective cannabis-based therapies, ... and Non-Executive Director, Peter Mountford , has ... primary responsibility for the European markets. ... his previous success in the emerging field of ...
(Date:5/4/2015)... and VANCOUVER, British Columbia ... OGXI ) announced today that it will report ... 14, 2015. Company management will host a conference call ... provide an overview of financial results, clinical development programs ... access the webcast, log on to the Investor Relations ...
Breaking Medicine Technology:Omeros Corporation to Announce First Quarter 2015 Financial Results on May 11, 2015 2InMed Engages Peter Mountford as Strategic Advisor 2InMed Engages Peter Mountford as Strategic Advisor 3InMed Engages Peter Mountford as Strategic Advisor 4
... CS, a cancer survivorship case management software program jointly ... ) and Equicare Health, Inc., has been included by ... in its "Best Practices Repository." The repository is a ... in the U.S. adopt rigorous standards for high-quality patient-centered ...
... May 29, 2012  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® tCGM System as a non-invasive, wireless, transdermal ... System for transdermal drug delivery, today announced that ... Echo Therapeutics will present at the Jefferies 2012 ...
Cached Medicine Technology:EQUICARE CS Cancer Survivorship Case Management Software Listed as a "Best Practices" Resource by the American College of Surgeons Commission on Cancer (COC) 2EQUICARE CS Cancer Survivorship Case Management Software Listed as a "Best Practices" Resource by the American College of Surgeons Commission on Cancer (COC) 3Echo Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference 2Echo Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference 3
Legionella IgG/M ELISA....
Measles IgM ELISA....
... The Wampole EBV ELISA test ... of assays for the determination ... tests for Viral Capsid Antigen ... Nuclear Antigen (EBNA). Most Wampole ...
Toxo IgG ELISA. All Wampole ELISA kits include the following: 12 x 8 well strips with breakaway wells, sample diluent, controls and calibrators, conjugate, TMB substrate, wash buffer, stop solution,...
Medicine Products: